Heart failure is one of the leading causes of death worldwide and has been singled out as
an emerging epidemic. 1, 2 With a 5-year survival rate of 50%, heart failure poses a …

There is a constant high demand for energy to sustain the continuous contractile activity of
the heart, which is met primarily by the β-oxidation of long-chain fatty acids. The control of …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

Background—Glucose-insulin-potassium infusions are beneficial in uncomplicated patients
with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular …

Cardiac ischemia and its consequences including heart failure, which itself has emerged as
the leading cause of morbidity and mortality in developed countries are accompanied by …

Background—The relationship between admission glucose levels and outcomes in older
diabetic and nondiabetic patients with acute myocardial infarction is not well defined …

BACKGROUND: Insulin resistance is present in the setting of congestive heart failure.
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and …

Diabetes mellitus is characterized by a high risk of atherothrombotic events. What is more,
venous thrombosis has also been found to occur more frequently in this patient group. This …

Objectives: This study sought to examine whether exenatide is capable of reducing
myocardial infarct size. Background: Exenatide is a glucagon-like peptide (GLP)-1 analogue …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence for the link between the use of intensive insulin therapy to achieve different …